Infliximab, a chimeric anti-TNF-α monoclonal antibody, was well tolerated and effectively improved index organ involvement without disease recurrence in a case study of refractory sarcoidosis (nine cases of patients who failed to improve despite moderate-to-high prednisone doses) [12]. Here, TNF is linked to sarcoidosis.